药物发现
生物医学
药学
药品
药物开发
制药工业
大数据
过程(计算)
计算机科学
人工智能
风险分析(工程)
数据科学
医学
数据挖掘
生物信息学
药理学
生物
操作系统
作者
Mingkun Lu,Jiayi Yin,Qi Zhu,Gaole Lin,Minjie Mou,Fuyao Liu,Ziqi Pan,Nanxin You,Xichen Lian,Fengcheng Li,Hongning Zhang,Lingyan Zheng,Wei Zhang,Hanyu Zhang,Zihao Shen,Zhen Gu,Honglin Li,Feng Zhu
出处
期刊:Engineering
[Elsevier]
日期:2023-04-28
卷期号:27: 37-69
被引量:42
标识
DOI:10.1016/j.eng.2023.01.014
摘要
Drug discovery and development affects various aspects of human health and dramatically impacts the pharmaceutical market. However, investments in a new drug often go unrewarded due to the long and complex process of drug research and development (R&D). With the advancement of experimental technology and computer hardware, artificial intelligence (AI) has recently emerged as a leading tool in analyzing abundant and high-dimensional data. Explosive growth in the size of biomedical data provides advantages in applying AI in all stages of drug R&D. Driven by big data in biomedicine, AI has led to a revolution in drug R&D, due to its ability to discover new drugs more efficiently and at lower cost. This review begins with a brief overview of common AI models in the field of drug discovery; then, it summarizes and discusses in depth their specific applications in various stages of drug R&D, such as target discovery, drug discovery and design, preclinical research, automated drug synthesis, and influences in the pharmaceutical market. Finally, the major limitations of AI in drug R&D are fully discussed and possible solutions are proposed.
科研通智能强力驱动
Strongly Powered by AbleSci AI